The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease.
about
MAO-B elevation in mouse brain astrocytes results in Parkinson's pathologyThe antioxidative effect of electro-acupuncture in a mouse model of Parkinson's diseaseSTEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's diseaseMitochondrial defects and oxidative stress in Alzheimer disease and Parkinson diseaseNeuroprotective Effects of Salidroside in the MPTP Mouse Model of Parkinson's Disease: Involvement of the PI3K/Akt/GSK3β PathwayMicroarray analysis of oxidative stress regulated genes in mesencephalic dopaminergic neuronal cells: relevance to oxidative damage in Parkinson's diseaseCHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonismProtein kinase D1 (PKD1) activation mediates a compensatory protective response during early stages of oxidative stress-induced neuronal degenerationHypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress.Dopaminergic Neurodegeneration in the Mouse Is Associated with Decrease of Viscoelasticity of Substantia Nigra Tissue.Targeting chelatable iron as a therapeutic modality in Parkinson's disease.Region-specific protein abundance changes in the brain of MPTP-induced Parkinson's disease mouse modelCell-based therapies for Parkinson's disease: past, present, and futureNeuroprotective effect of long-term NDI1 gene expression in a chronic mouse model of Parkinson disorder.Parkinson's disease: Exit toxins, enter geneticsProtective Role of rAAV-NDI1, Serotype 5, in an Acute MPTP Mouse Parkinson's Model.Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection.Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration.Adult bone marrow neural crest stem cells and mesenchymal stem cells are not able to replace lost neurons in acute MPTP-lesioned mice.Protein kinase D1 (PKD1) phosphorylation promotes dopaminergic neuronal survival during 6-OHDA-induced oxidative stress.Absence of glia maturation factor protects dopaminergic neurons and improves motor behavior in mouse model of parkinsonismAngiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra.Mitochondrial permeability transition pore component cyclophilin D distinguishes nigrostriatal dopaminergic death paradigms in the MPTP mouse model of Parkinson's disease.Toxin models of mitochondrial dysfunction in Parkinson's disease.Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson's disease.D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease.Chelators in the treatment of iron accumulation in Parkinson's disease.Physiological phenotype and vulnerability in Parkinson's diseaseASIC1a Deficient Mice Show Unaltered Neurodegeneration in the Subacute MPTP Model of Parkinson Disease.Mitochondrial respiratory complex I: structure, function and implication in human diseases.N-terminal cleavage of the mitochondrial fusion GTPase OPA1 occurs via a caspase-independent mechanism in cerebellar granule neurons exposed to oxidative or nitrosative stress.Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?Validity of the MPTP-Treated Mouse as a Model for Parkinson's Disease.Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic interventionDistinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.Catalase and glutathione peroxidase mimics.Mitochondrial toxins in Basal Ganglia disorders: from animal models to therapeutic strategies.Synthesis and neuroprotective action of xyloketal derivatives in Parkinson's disease models.Caloric Restriction Protects against Lactacystin-Induced Degeneration of Dopamine Neurons Independent of the Ghrelin Receptor.Neurogenesis in Neurotoxin-induced Animal Models for Parkinson's Disease-A Review of the Current Status.
P2860
Q27301926-F55EB7AC-B3BA-4960-9B07-3BCF081B4D2EQ27342258-CB804D77-5B7B-4259-A754-7DA0293B2E2DQ28255428-84EAC4CA-270C-4EE3-88C8-6BAE4321ED07Q28280353-D574F353-BFD9-4BE8-84B2-26E4B1715111Q28390865-E831C97E-ABA7-4284-9B4D-DB58B04D131CQ28573057-BD65F7EA-52B2-4199-BB1B-8A6B0A06D4CCQ28579022-6ED5018C-7D18-40E5-87F0-F908B18E5984Q28582417-2B7D18C9-3250-4D7B-8279-854CF18F8F54Q28593258-E7550856-45B6-408C-8E95-1F4E56C08802Q30375763-CA329615-4C12-4876-833F-641F0D8FDAA4Q33768106-47E0C004-187A-4D3C-828B-15B1E3962267Q33810589-82687B87-E2D6-4506-8FE5-D36EA234B4CAQ33818127-76C5CB83-9242-4881-BFCE-3AAFE5965CAFQ34129621-C2E0CCA1-4172-4327-B64E-307BC5FAEE4DQ34140428-AB5246B3-6F41-4F35-8210-D4508169E668Q34423923-2790967C-0C25-476F-86E9-1F2203DEF44CQ34460675-7182DB32-D651-48A9-9093-BB676D1D18E1Q34583071-973A27E3-6401-4E4B-99BF-C16CC4B6E001Q34760743-1223DAB6-332D-4A88-99E6-0C9665F1F9A3Q35164624-0894BE07-60C9-48AE-A79E-787A113930FDQ35587423-48D8170B-8583-496E-9563-86BC9B822703Q35613025-3236E388-E84A-4F19-A5F1-5883D4EEBD15Q35799121-F0500917-AFED-4161-BF11-98D80BFB133BQ35799141-CD56148F-616B-490A-AC26-5C67422ED7DCQ35869111-FD52478F-2FC4-435D-B6BE-056C7197AC0BQ35919815-96F5A864-86FC-4D0D-A161-6EAAC265D9E8Q36056203-690029E0-02D0-48A7-9EE7-70B416341B14Q36065850-00F2F79A-4493-4206-AFA8-EEA6C2881E13Q36184308-FE43905C-8B45-4FB3-82F4-958129E9B4A4Q36444688-41699C5B-E707-4C8C-B07F-ACC9B6F728A9Q36617944-F6A1C9EA-23C6-4FE1-84C9-30709D1B0D65Q36648907-B2B3DF0B-3163-48D6-91FE-31CDC0A2B746Q36680273-8E1FB00E-D1C0-49BB-9FD5-9926E798499CQ36919403-A642DA75-4614-484E-AE9A-80E9908A51C8Q37076753-0B5EA86E-C8DB-4E4F-8D2E-F779392B9B4CQ37132691-414FFBF2-1310-426C-BEA7-D0FC3001F136Q37211755-45B976CF-81C2-48E5-95DD-13ECB591113AQ37425008-B212AE1E-65FC-4902-AAE6-9618698C65E2Q37729142-D7641052-0718-4283-BD9D-8B34E93566C4Q37978305-15CFE170-5CB7-4765-BD06-E26CED599AA1
P2860
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The 1-methyl-4-phenyl-1,2,3,6- ...... enesis of Parkinson's disease.
@ast
The 1-methyl-4-phenyl-1,2,3,6- ...... enesis of Parkinson's disease.
@en
type
label
The 1-methyl-4-phenyl-1,2,3,6- ...... enesis of Parkinson's disease.
@ast
The 1-methyl-4-phenyl-1,2,3,6- ...... enesis of Parkinson's disease.
@en
prefLabel
The 1-methyl-4-phenyl-1,2,3,6- ...... enesis of Parkinson's disease.
@ast
The 1-methyl-4-phenyl-1,2,3,6- ...... enesis of Parkinson's disease.
@en
P1476
The 1-methyl-4-phenyl-1,2,3,6- ...... enesis of Parkinson's disease.
@en
P2093
Miquel Vila
P304
P407
P577
2003-06-01T00:00:00Z